Mesirow Financial Investment Management, Inc.
Position in EW — Edwards Lifesciences Corp
CIK 1469475
CHICAGO, IL
Position in EW
as of Mar 31, 2026
· filed Apr 21, 2026
Position Value
$395,515
-$25,790 QoQ
Shares Held
4,939
-0.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EW Over Time
Shares Held
Position Value (USD)
Position in Medical Devices
Healthcare · as of Mar 31, 2026Mesirow Financial Investment Management, Inc. holds $39,271,214 across 7 Medical Devices names. EW ranks #3 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SYK |
Stryker Corp
|
64,583 | $21,221,327 | |
| 2 | ABT |
Abbott Laboratories
|
163,286 | $16,764,573 | |
| 3 | EW |
Edwards Lifesciences Corp
This page
|
4,939 | $395,515 | |
| 4 | GMED |
Globus Medical Inc
|
3,397 | $292,685 | |
| 5 | MDT |
Medtronic plc
|
3,243 | $281,005 | |
| 6 | GEHC |
GE HealthCare Technologies Inc.
|
3,754 | $267,209 | |
| 7 | NSPR |
InspireMD, Inc.
|
30,000 | $48,900 |
All Filings in EW
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $395,515 | 4,939 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $421,305 | 4,942 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $398,726 | 5,127 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $400,982 | 5,127 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $364,864 | 5,034 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $376,220 | 5,082 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $335,361 | 5,082 | Shares | Sole | 2024-11-01 | |
| 2024-06-30 | $469,424 | 5,082 | Shares | Sole | 2024-08-09 | |
| 2024-03-31 | $485,635 | 5,082 | Shares | Sole | 2024-04-25 | |
| 2023-12-31 | $1,093,120 | 14,336 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||